A phase 3, multicenter, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder

1. Gasior, M.
2. Hudson, J.
3. Quintero, J.
4. Ferreira-Cornwell, M.C.
5. Radewonuk, J.
6. McElroy, S.L.